NRIX · Nurix Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.25M | - | $7.89M | $44.06M | $16.59M | - | $18.47M | $12.09M | $16.59M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $84.14M | - | $86.12M | $78.10M | $69.66M | - | $55.48M | $48.92M | $50.01M | - |
| SG&A | $14.61M | - | $13.16M | $14.28M | $11.65M | - | $11.72M | $11.71M | $11.80M | - |
| Total Operating Expenses | $98.75M | - | $99.28M | $92.38M | $81.32M | - | $67.20M | $60.63M | $61.80M | - |
| D&A | $2.20M | - | - | - | $2.35M | - | - | - | $2.04M | - |
| Operating Income | ($92.50M) | - | ($91.39M) | ($48.32M) | ($62.86M) | - | ($54.61M) | ($48.54M) | ($45.22M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $760.0K | $0 | - | $82.0K | $90.0K | $90.0K | - |
| Net Income | ($87.17M) | - | ($86.42M) | ($43.46M) | ($56.35M) | - | ($48.96M) | ($44.55M) | ($41.52M) | - |
| EPS - Basic | ($0.79) | - | ($1.03) | ($0.52) | ($0.67) | - | ($0.67) | ($0.71) | ($0.76) | - |
| EPS - Diluted | ($0.79) | - | ($1.03) | ($0.52) | ($0.67) | - | ($0.67) | ($0.71) | ($0.76) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $71.19M | $246.96M | $78.44M | $84.26M | $75.92M | $110.00M | $99.04M | $116.79M | $49.81M | $54.63M |
| Accounts Receivable | - | - | - | $0 | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $10.29M | $11.21M | $8.61M | $5.95M | $8.40M | $11.48M | $3.92M | $2.81M | $5.92M | $6.40M |
| Current Assets | $554.39M | $606.82M | $440.60M | $515.33M | $563.70M | $619.39M | $456.04M | $450.22M | $250.97M | $295.50M |
| Total Assets | $636.13M | $688.13M | $522.47M | $591.55M | $615.04M | $669.34M | $513.60M | $511.03M | $312.67M | $355.60M |
| Current Liabilities | $92.20M | $86.47M | $82.35M | $75.61M | $89.99M | $95.85M | $86.30M | $80.78M | $87.62M | $86.96M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $155.24M | $149.39M | $150.22M | $143.95M | $134.13M | $142.35M | $136.74M | $140.34M | $143.93M | $155.10M |
| Stockholders' Equity | $480.89M | $538.75M | $372.25M | $447.60M | $480.92M | $526.99M | $376.86M | $370.69M | $168.75M | $200.49M |
| Retained Earnings | ($1.09B) | ($1.00B) | ($925.00M) | ($838.58M) | ($795.12M) | ($738.77M) | ($680.22M) | ($631.26M) | ($586.72M) | ($545.20M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($71.91M) | - | - | - | ($61.09M) | - | - | - | ($41.95M) | - |
| Investing Cash Flow | ($123.83M) | - | - | - | $25.53M | - | - | - | $35.51M | - |
| Financing Cash Flow | $19.98M | - | - | - | $1.47M | - | - | - | $1.62M | - |
| CapEx | $1.04M | - | - | - | $3.48M | - | - | - | $2.88M | - |
| Free Cash Flow | ($72.96M) | - | - | - | ($64.57M) | - | - | - | ($44.84M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -1479.4% | - | -1157.7% | -109.7% | -379.0% | - | -295.7% | -401.4% | -272.6% | - |
| EBITDA margin | -1444.3% | - | - | - | -364.9% | - | - | - | -260.3% | - |
| Net margin | -1394.3% | - | -1094.8% | -98.7% | -339.8% | - | -265.1% | -368.4% | -250.3% | - |
| Free cash flow margin | -1167.0% | - | - | - | -389.3% | - | - | - | -270.3% | - |
| FCF / Net income | 0.84 | - | - | - | 1.15 | - | - | - | 1.08 | - |
| R&D / Revenue | 1345.8% | - | 1091.0% | 177.3% | 420.0% | - | 300.4% | 404.6% | 301.5% | - |
| SG&A / Revenue | 233.7% | - | 166.7% | 32.4% | 70.3% | - | 63.5% | 96.8% | 71.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -13.7% | - | -16.5% | -7.3% | -9.2% | - | -9.5% | -8.7% | -13.3% | - |
| Return on equity | -18.1% | - | -23.2% | -9.7% | -11.7% | - | -13.0% | -12.0% | -24.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.01 | 7.02 | 5.35 | 6.82 | 6.26 | 6.46 | 5.28 | 5.57 | 2.86 | 3.40 |
| Quick ratio | 6.01 | 7.02 | 5.35 | 6.82 | 6.26 | 6.46 | 5.28 | 5.57 | 2.86 | 3.40 |
| Cash ratio | 0.77 | 2.86 | 0.95 | 1.11 | 0.84 | 1.15 | 1.15 | 1.45 | 0.57 | 0.63 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.32 | 1.28 | 1.40 | 1.32 | 1.28 | 1.27 | 1.36 | 1.38 | 1.85 | 1.77 |
| Liabilities / Assets | 0.24 | 0.22 | 0.29 | 0.24 | 0.22 | 0.21 | 0.27 | 0.27 | 0.46 | 0.44 |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | - | 0.02 | 0.07 | 0.03 | - | 0.04 | 0.02 | 0.05 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | 0d | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.7x | - | 2.1x | 2.0x | 2.7x | - | 4.9x | 2.7x | 4.0x | - |
| P / S | 281.2x | - | 99.6x | 20.2x | 77.8x | - | 99.3x | 81.2x | 40.9x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -62.3% | - | -57.3% | 264.3% | 0.0% | - | 0.0% | -60.6% | 30.7% | - |
| Revenue CAGR (3y) | -21.0% | - | -9.9% | 56.8% | 19.9% | - | 21.7% | 19.5% | 49.0% | - |
| Revenue CAGR (5y) | 4.5% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -47.1% | - | -67.3% | 0.4% | -39.0% | - | -36.5% | -81.4% | -5.3% | - |
| Net income growth (YoY) | -54.7% | - | -76.5% | 2.4% | -35.7% | - | -32.4% | -83.5% | -1.9% | - |
| EPS growth (YoY) | -17.9% | - | -53.7% | 26.8% | 11.8% | - | 1.5% | -57.8% | -1.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -13.0% | - | - | - | -44.0% | - | - | - | 11.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -0.0% | 2.2% | -1.2% | 20.7% | 185.0% | 162.8% | 61.2% | 42.6% | -38.4% | -34.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-11-30.
Product / service
$83.98M totalCollaboration Revenue$53.98M · 64.3%
License Revenue$30.00M · 35.7%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Nurix Therapeutics against the 5 most active filers in the same SIC group.